Contact

All Stories

  1. Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease

    Article • The Journal of Prevention of Alzheimer s Disease, January 2026, Elsevier

    Dr. Raymond Scott Turner

  2. Alzheimer's disease polygenic risk in early‐ and late‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, January 2026, Wiley

    Dr. Raymond Scott Turner

  3. Tablet‐based Cognitive Assessment Tool (TabCAT) in a multisite study of early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, December 2025, Wiley

    Dr Konstantinos Chiotis, Dr. Raymond Scott Turner

  4. Estimation of reference curves for brain atrophy and analysis of robustness to machine effects

    Article • Scientific Reports, October 2025, Springer Science + Business Media

    Dr. Raymond Scott Turner

  5. The financial consequences of undiagnosed memory disorders

    Article • Journal of Financial Economics, October 2025, Elsevier

    Dr. Raymond Scott Turner

  6. First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population

    Article • Alzheimer s Research & Therapy, August 2025, Springer Science + Business Media

    Dr. Raymond Scott Turner

  7. Speech production as an artificial intelligence-based ‘process’ measure of cognition sensitive to mild cognitive impairment and Alzheimer’s disease

    Article • The Clinical Neuropsychologist, July 2025, Taylor & Francis

    Dr. Raymond Scott Turner

  8. Safety, Cognitive, and Behavioral Outcomes in Patients with Dementia with Lewy Bodies Treated with Nilotinib

    Article • Journal of Clinical Medicine, June 2025, MDPI AG

    Dr. Raymond Scott Turner

  9. Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease

    Article • International Journal of Molecular Sciences, May 2025, MDPI AG

    Dr. Raymond Scott Turner

  10. Mouse models of Anti-Aβ immunotherapies

    Article • Molecular Neurodegeneration, May 2025, Springer Science + Business Media

    Dr. Raymond Scott Turner

  11. Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials

    Article • The Journal of Prevention of Alzheimer s Disease, April 2025, Elsevier

    Dr. Raymond Scott Turner

  12. Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts

    Article • Annals of Neurology, March 2025, Wiley

    Dr. Raymond Scott Turner

  13. Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer’s disease: a neuropsychological data-driven approach

    Article • Alzheimer s Research & Therapy, February 2025, Springer Science + Business Media

    Dr. Raymond Scott Turner

  14. Dissociable spatial topography of cortical atrophy in early‐onset and late‐onset Alzheimer's disease: A head‐to‐head comparison of the LEADS and ADNI cohorts

    Article • Alzheimer s & Dementia, February 2025, Wiley

    Dr. Raymond Scott Turner

  15. Differences in baseline cognitive performance between participants with early‐onset and late‐onset Alzheimer's disease: Comparison of LEADS and ADNI

    Article • Alzheimer s & Dementia, December 2024, Wiley

    Dr. Raymond Scott Turner

  16. Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS

    Article • Alzheimer s & Dementia, December 2024, Wiley

    Dr. Raymond Scott Turner

  17. Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer’s Disease

    Article • Journal of Alzheimer’s Disease, October 2024, IOS Press

    Dr. Raymond Scott Turner

  18. Aging as a target for the prevention and treatment of Alzheimer’s disease

    Article • Frontiers in Neurology, April 2024, Frontiers

    Dr. Raymond Scott Turner

  19. Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder

    Article • Neurology, January 2024, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  20. Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy

    Article • Journal of Neurochemistry, January 2024, Wiley

    Dr. Raymond Scott Turner

  21. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes

    Article • Alzheimer s & Dementia, December 2023, Wiley

    Dr. Raymond Scott Turner

  22. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2023, New England Journal of Medicine (NEJM/MMS)

    Dr. Raymond Scott Turner

  23. The Sporadic Early‐onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) Cohort

    Article • Alzheimer s & Dementia, October 2023, Wiley

    Dr. Raymond Scott Turner

  24. Pathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort

    Article • Alzheimer s & Dementia, October 2023, Wiley

    Dr. Raymond Scott Turner

  25. An explainable machine learning model of cognitive decline derived from speech

    Article • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, October 2023, Wiley

    Dr. Raymond Scott Turner

  26. Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)

    Article • Alzheimer s & Dementia, September 2023, Wiley

    Dr. Raymond Scott Turner

  27. Influence of amyloid and diagnostic syndrome on non‐traditional memory scores in early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, August 2023, Wiley

    Dr. Raymond Scott Turner

  28. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment

    Article • Annals of Clinical and Translational Neurology, August 2023, Wiley

    Dr. Raymond Scott Turner

  29. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, July 2023, Wiley

    Dr. Raymond Scott Turner

  30. Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study

    Article • Alzheimer s & Dementia, July 2023, Wiley

    Dr. Raymond Scott Turner

  31. White matter hyperintensities are higher among early‐onset Alzheimer's disease participants than their cognitively normal and early‐onset nonAD peers: Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)

    Article • Alzheimer s & Dementia, July 2023, Wiley

    Dr. Raymond Scott Turner

  32. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort

    Article • Alzheimer s & Dementia, June 2023, Wiley

    Dr. Raymond Scott Turner

  33. Profiling baseline performance on the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection

    Article • Alzheimer s & Dementia, May 2023, Wiley

    Dr. Raymond Scott Turner

  34. Learning slopes in early‐onset Alzheimer's disease

    Article • Alzheimer s & Dementia, May 2023, Wiley

    Dr. Raymond Scott Turner

  35. Matrix disequilibrium in Alzheimer’s disease and conditions that increase Alzheimer’s disease risk

    Article • Frontiers in Neuroscience, May 2023, Frontiers

    Dr. Raymond Scott Turner

  36. Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease

    Article • Journal of Neuroinflammation, May 2023, Springer Science + Business Media

    Dr. Raymond Scott Turner

  37. CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice

    Article • Neurobiology of Disease, April 2023, Elsevier

    Dr. Raymond Scott Turner

  38. Inhibition of discoidin domain receptor (DDR)-1 with nilotinib induces autophagy and reduces inflammation and vascular fibrosis in Alzheimer’s disease

    Article • March 2023, Research Square

    Dr. Raymond Scott Turner

  39. Increasing access to cognitive screening in the elderly: Applying natural language processing methods to speech collected over the telephone

    Article • Cortex, November 2022, Elsevier

    Dr. Raymond Scott Turner

  40. CCR5 deficiency normalizes TIMP levels, working memory, and gamma oscillation power in APOE4 targeted replacement mice

    Article • July 2022, Cold Spring Harbor Laboratory Press

    Dr. Raymond Scott Turner

  41. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

    Article • Frontiers in Neurology, March 2022, Frontiers

    Dr. Raymond Scott Turner

  42. Corrigendum: A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease

    Article • Frontiers in Aging Neuroscience, March 2022, Frontiers

    Dr. Raymond Scott Turner

  43. Class-Based Antiretroviral Exposure and Cognition Among Women Living with HIV

    Article • AIDS Research and Human Retroviruses, March 2022, Mary Ann Liebert Inc

    Dr. Raymond Scott Turner

  44. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

    Article • Alzheimer s & Dementia Translational Research & Clinical Interventions, January 2022, Wiley

    Dr. Raymond Scott Turner

  45. Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease

    Article • PLOS One, June 2021, PLOS

    Dr. Raymond Scott Turner

  46. Low CD4 nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV

    Article • AIDS, February 2021, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  47. Research Attitudes Questionnaire scores predict Alzheimer’s disease clinical trial dropout

    Article • Clinical Trials, January 2021, SAGE Publications

    Dr. Raymond Scott Turner

  48. Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer’s Disease

    Article • Aging and Disease, January 2021, Aging and Disease

    Dr. Raymond Scott Turner

  49. Acceptability of collecting speech samples from the elderly via the telephone

    Article • Digital Health, January 2021, SAGE Publications

    Dr. Raymond Scott Turner

  50. A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease

    Article • Frontiers in Aging Neuroscience, December 2020, Frontiers

    Dr. Raymond Scott Turner

  51. Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias

    Article • Frontiers in Neurology, June 2020, Frontiers

    Dr. Raymond Scott Turner

  52. Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease

    Article • Annals of Neurology, May 2020, Wiley

    Dr. Raymond Scott Turner

  53. Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimer’s disease

    Article • May 2020, Cold Spring Harbor Laboratory Press

    Dr. Raymond Scott Turner

  54. FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease

    Article • Nature Communications, January 2020, Springer Science + Business Media

    Dr. Raymond Scott Turner

  55. A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data

    Article • Scientific Reports, December 2019, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  56. Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease

    Article • JAMA Neurology, November 2019, American Medical Association (AMA)

    Dr. Raymond Scott Turner

  57. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease

    Article • JAMA Neurology, October 2019, American Medical Association (AMA)

    Dr. Raymond Scott Turner

  58. Multimodal Hippocampal Subfield Grading For Alzheimer’s Disease Classification

    Article • Scientific Reports, September 2019, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  59. Non-coding variability at the APOE locus contributes to the Alzheimer’s risk

    Article • Nature Communications, July 2019, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  60. Periprocedural Heparin During Endovascular Treatment of Tandem Lesions in Patients with Acute Ischemic Stroke: A Propensity Score Analysis from TITAN Registry

    Article • Cardiovascular Radiology, May 2019, Springer Science + Business Media

    Dr. Raymond Scott Turner

  61. The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory

    Article • Nature Communications, April 2019, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  62. White matter in different regions evolves differently during progression to dementia

    Article • Neurobiology of Aging, April 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  63. A blood-based signature of cerebrospinal fluid Aβ1–42 status

    Article • Scientific Reports, March 2019, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  64. Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model

    Article • Frontiers in Neuroscience, February 2019, Frontiers

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  65. The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE ε4 in Mild Cognitive Impairment

    Article • Frontiers in Aging Neuroscience, February 2019, Frontiers

    Dr. Raymond Scott Turner

  66. Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI

    Article • PLOS One, February 2019, PLOS

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  67. A review of statistical methods in imaging genetics

    Article • Canadian Journal of Statistics, February 2019, Wiley

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  68. Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3

    Article • Frontiers in Neuroinformatics, February 2019, Frontiers

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  69. Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles

    Article • Frontiers in Neurology, February 2019, Frontiers

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  70. Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics

    Article • Scientific Reports, February 2019, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  71. Random forest prediction of Alzheimer’s disease using pairwise selection from time series data

    Article • PLOS One, February 2019, PLOS

    Dr Paul J Moore, Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  72. Predicting Alzheimer’s disease progression using multi-modal deep learning approach

    Article • Scientific Reports, February 2019, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  73. Neural activity during a simple reaching task in macaques is counter to gating and rebound in basal ganglia-thalamic communication

    Article • February 2019, openRxiv

    Dr. Robert S. Turner, Dr. Raymond Scott Turner

  74. Translating Alzheimer's disease–associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs

    Article • Neurobiology of Aging, February 2019, Elsevier

    Dr David W Fardo, Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  75. Amyloid beta–positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity

    Article • Neurobiology of Aging, February 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  76. Association of CSF CD40 levels and synaptic degeneration across the Alzheimer’s disease spectrum

    Article • Neuroscience Letters, February 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  77. Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling

    Article • NeuroImage, February 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  78. Functional signature of conversion of patients with mild cognitive impairment

    Article • Neurobiology of Aging, February 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  79. Medical Image Imputation From Image Collections

    Article • IEEE Transactions on Medical Imaging, February 2019, Institute of Electrical & Electronics Engineers (IEEE)

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  80. QuickNAT: A fully convolutional network for quick and accurate segmentation of neuroanatomy

    Article • NeuroImage, February 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  81. MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders

    Article • Aging, January 2019, Impact Journals, LLC

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  82. Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer’s Disease

    Article • Frontiers in Neuroscience, January 2019, Frontiers

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  83. A δ Homolog for Dementia Case Finding with Replication in the Alzheimer’s Disease Neuroimaging Initiative

    Article • Journal of Alzheimer’s Disease, January 2019, IOS Press

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  84. Next Generation Sequencing Analysis in Early Onset Dementia Patients

    Article • Journal of Alzheimer’s Disease, January 2019, IOS Press

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  85. Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment

    Article • NeuroImage Clinical, January 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  86. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data

    Article • NeuroImage Clinical, January 2019, Elsevier

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  87. A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative

    Article • Human Brain Mapping, December 2018, Wiley

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  88. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study

    Article • Journal of Clinical Oncology, November 2018, American Society of Clinical Oncology (ASCO)

    Dr. Raymond Scott Turner

  89. Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia

    Article • Molecular Neurobiology, November 2018, Springer Science + Business Media

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  90. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease

    Article • European Journal of Pediatrics, October 2018, Springer Science + Business Media

    FEDERICO MASSA, Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  91. Accurate risk estimation of β‐amyloid positivity to identify prodromal Alzheimer's disease: Cross‐validation study of practical algorithms

    Article • Alzheimer s & Dementia, October 2018, Wiley

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  92. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome

    Article • Alzheimer s & Dementia, October 2018, Wiley

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  93. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers

    Article • Alzheimer s & Dementia, October 2018, Wiley

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  94. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative

    Article • Alzheimer s & Dementia, October 2018, Wiley

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  95. Cortico-basal-ganglia communication: Temporally structured activity for selective motor control

    Article • September 2018, openRxiv

    Dr. Raymond Scott Turner

  96. A Novel Method to Estimate Long‐Term Chronological Changes From Fragmented Observations in Disease Progression

    Article • Clinical Pharmacology & Therapeutics, August 2018, Wiley

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  97. Communicability disruption in Alzheimer’s disease connectivity networks

    Article • Journal of Complex Networks, May 2018, Oxford University Press (OUP)

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  98. Long-Term maintenance of anomia treatment effects in primary progressive aphasia

    Article • Neuropsychological Rehabilitation, January 2018, Taylor & Francis

    Dr. Raymond Scott Turner

  99. Longitudinal Functional Brain Mapping in Supernormals

    Article • Cerebral Cortex, November 2017, Oxford University Press (OUP)

    Professor of Clinical Psychiatry Adrian PREDA, Dr. Raymond Scott Turner

  100. Does treatment with resveratrol improve outcomes in patients with Alzheimer's disease?

    Article • Annals of the New York Academy of Sciences, August 2017, Wiley

    Dr. Raymond Scott Turner

  101. Polo-like kinase 2 phosphorylation of amyloid precursor protein regulates activity-dependent amyloidogenic processing

    Article • Neuropharmacology, May 2017, Elsevier

    Dr. Raymond Scott Turner

  102. Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease

    Article • Neurobiology of Aging, March 2017, Elsevier

    Dr. Raymond Scott Turner

  103. 11C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease

    Article • Neurology, February 2017, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  104. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

    Article • Journal of Neuroinflammation, January 2017, Springer Science + Business Media

    Dr. Raymond Scott Turner

  105. The BIOCARD Index

    Article • Alzheimer Disease & Associated Disorders, January 2017, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  106. Exploratory Clustering for Patient Subpopulation Discovery

    Article • January 2017, IOS Press

    Dr. Raymond Scott Turner

  107. 11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease

    Article • Neurobiology of Aging, August 2016, Elsevier

    Dr. Raymond Scott Turner

  108. Hexa (ethylene glycol) derivative of benzothiazole aniline promotes dendritic spine formation through the RasGRF1–Ras dependent pathway

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, February 2016, Elsevier

    Dr. Raymond Scott Turner

  109. An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition

    Article • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, January 2016, Wiley

    Dr. Raymond Scott Turner

  110. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

    Article • Neurology, September 2015, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  111. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer’s disease models

    Article • Neuroscience, September 2015, Elsevier

    Dr. Raymond Scott Turner

  112. Corrigendum to “A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease” [Exp. Neurol. 252 (2014) 105–113]

    Article • Experimental Neurology, November 2014, Elsevier

    Dr. Raymond Scott Turner

  113. Correction: Megill et al., A Tetra(Ethylene Glycol) Derivative of Benzothiazole Aniline Enhances Ras-Mediated Spinogenesis

    Article • Journal of Neuroscience, October 2014, Society for Neuroscience

    Dr. Raymond Scott Turner

  114. Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype

    Article • Current Alzheimer Research, September 2014, Bentham Science Publishers

    Dr. Raymond Scott Turner

  115. Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?

    Article • Journal of Clinical Oncology, June 2014, American Society of Clinical Oncology (ASCO)

    Dr. Raymond Scott Turner

  116. A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease

    Article • Experimental Neurology, February 2014, Elsevier

    Dr. Raymond Scott Turner

  117. Cognitive Effects of Cancer and Its Treatments at the Intersection of Aging: What Do We Know; What Do We Need to Know?

    Article • Seminars in Oncology, December 2013, Elsevier

    Dr. Raymond Scott Turner

  118. Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking

    Article • Biochemical and Biophysical Research Communications, October 2013, Elsevier

    Dr. Raymond Scott Turner

  119. Remediation and Prophylaxis of Anomia in Primary Progressive Aphasia

    Article • Procedia - Social and Behavioral Sciences, October 2013, Elsevier

    Dr. Raymond Scott Turner

  120. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease

    Article • Brain, June 2013, Oxford University Press (OUP)

    Dr. Raymond Scott Turner

  121. A Tetra(Ethylene Glycol) Derivative of Benzothiazole Aniline Enhances Ras-Mediated Spinogenesis

    Article • Journal of Neuroscience, May 2013, Society for Neuroscience

    Dr. Raymond Scott Turner

  122. Coexisting adult polyglucosan body disease with frontotemporal lobar degeneration with transactivation response DNA-binding protein-43 (TDP-43)-positive neuronal inclusions

    Article • Neurocase, February 2013, Taylor & Francis

    Dr. Raymond Scott Turner

  123. Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease

    Article • Experimental Neurology, January 2013, Elsevier

    Dr. Raymond Scott Turner

  124. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease

    Article • Journal of Neurochemistry, November 2012, Wiley

    Dr. Raymond Scott Turner

  125. Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study

    Article • Neurobiology of Aging, December 2011, Elsevier

    Dr. Raymond Scott Turner

  126. Age-related loss of noradrenergic neurons in the brains of triple transgenic mice

    Article • AGE, November 2011, Springer Science + Business Media

    Dr. Raymond Scott Turner

  127. Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice

    Article • Brain Research, September 2011, Elsevier

    Dr. Raymond Scott Turner

  128. Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic Errors

    Article • Archives of Neurology, March 2011, American Medical Association (AMA)

    Dr. Raymond Scott Turner

  129. ApoE Receptor 2 Regulates Synapse and Dendritic Spine Formation

    Article • PLOS One, February 2011, PLOS

    Dr. Raymond Scott Turner

  130. Validation of Consensus Panel Diagnosis in Dementia

    Article • Archives of Neurology, December 2010, American Medical Association (AMA)

    Dr. Raymond Scott Turner

  131. Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines

    Article • Neuroscience, August 2010, Elsevier

    Dr. Raymond Scott Turner

  132. ApoE mimetic peptide decreases Aβ production in vitro and in vivo

    Article • Molecular Neurodegeneration, January 2010, Springer Science + Business Media

    Dr. Raymond Scott Turner

  133. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease

    Article • Journal of Neuroinflammation, January 2010, Springer Science + Business Media

    Dr. Raymond Scott Turner

  134. ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo

    Article • Journal of Neuroscience, December 2009, Society for Neuroscience

    Dr. Raymond Scott Turner

  135. X11α haploinsufficiency enhances Aβ amyloid deposition in Alzheimer's disease transgenic mice

    Article • Neurobiology of Disease, October 2009, Elsevier

    Dr. Raymond Scott Turner

  136. The cytoplasmic adaptor protein X11  and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement

    Article • The FASEB Journal, August 2009, Federation of American Societies For Experimental Biology (FASEB)

    Dr. Raymond Scott Turner

  137. Amyloid-β-Induced Ion Flux in Artificial Lipid Bilayers and Neuronal Cells: Resolving a Controversy

    Article • Neurotoxicity Research, March 2009, Springer Science + Business Media

    Dr. Raymond Scott Turner

  138. Amyloid-β Ion Channels in Artificial Lipid Bilayers and Neuronal Cells. Resolving a Controversy

    Article • Biophysical Journal, February 2009, Elsevier

    Dr. Raymond Scott Turner

  139. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease

    Article • Brain, October 2007, Oxford University Press (OUP)

    Dr. Raymond Scott Turner

  140. Alzheimer's Disease

    Article • Seminars in Neurology, November 2006, Thieme Publishing Group

    Dr. Raymond Scott Turner

  141. P3-070 Adding FDG-PET to clinical history and examination improves the accuracy of dementia diagnosis

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr. Raymond Scott Turner

  142. P3-065 FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr. Raymond Scott Turner

  143. O4-04-05 X11alpha/mint-1 modulates gamma-cleavage of amyloid precursor protein

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr. Raymond Scott Turner

  144. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?

    Article • Experimental Neurology, February 2004, Elsevier

    Dr. Raymond Scott Turner

  145. X11α impairs γ‐ but not β‐cleavage of amyloid precursor protein

    Article • Journal of Neurochemistry, January 2004, Wiley

    Dr. Raymond Scott Turner

  146. A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging

    Article • Statistics in Medicine, January 2004, Wiley

    Dr. Raymond Scott Turner

  147. Biomarkers of alzheimer’s disease and mild cognitive impairment: are we there yet?

    Article • Experimental Neurology, September 2003, Elsevier

    Dr. Raymond Scott Turner

  148. X11α modulates secretory and endocytic trafficking and metabolism of amyloid precursor protein: mutational analysis of the yenpty sequence

    Article • Neuroscience, August 2003, Elsevier

    Dr. Raymond Scott Turner

  149. Idiopathic Rapid Eye Movement Sleep Behavior Disorder Is a Harbinger of Dementia with Lewy Bodies

    Article • Journal of Geriatric Psychiatry and Neurology, December 2002, SAGE Publications

    Dr. Raymond Scott Turner

  150. Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease

    Article • Learning & Memory, September 2002, Cold Spring Harbor Laboratory Press

    Dr. Raymond Scott Turner

  151. Inherited dementias

    Article • Neurologic Clinics, August 2002, Elsevier

    Dr. Raymond Scott Turner

  152. Synergistic Effects of Munc18a and X11 Proteins on Amyloid Precursor Protein Metabolism

    Article • Journal of Biological Chemistry, May 2002, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  153. Spontaneous intracranial hypotension causing reversible frontotemporal dementia

    Article • Neurology, April 2002, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  154. ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways

    Article • Journal of Neurochemistry, March 2002, Wiley

    Dr. Raymond Scott Turner

  155. Stable β-Secretase Activity and Presynaptic Cholinergic Markers During Progressive Central Nervous System Amyloidogenesis in Tg2576 Mice

    Article • American Journal Of Pathology, February 2002, Elsevier

    Dr. Raymond Scott Turner

  156. Differentiated Human NT2-N Neurons Possess a High Intracellular Content of myo-Inositol

    Article • Journal of Neurochemistry, December 2001, Wiley

    Dr. Raymond Scott Turner

  157. Alzheimer’s Disease in Man and Transgenic Mice

    Article • American Journal Of Pathology, March 2001, Elsevier

    Dr. Raymond Scott Turner

  158. The pathology of REM sleep behavior disorder with comorbid Lewy body dementia

    Article • Neurology, December 2000, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  159. The Protease Inhibitor, MG132, Blocks Maturation of the Amyloid Precursor Protein Swedish Mutant Preventing Cleavage by β-Secretase

    Article • Journal of Biological Chemistry, November 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  160. Modulation of Amyloid Precursor Protein Metabolism by X11α/Mint-1

    Article • Journal of Biological Chemistry, September 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  161. FORUM What Persian Gulf War Syndrome?

    Article • The Clinical Neuropsychologist, August 2000, Taylor & Francis

    Dr. Raymond Scott Turner

  162. Identification of an Evolutionarily Conserved Heterotrimeric Protein Complex Involved in Protein Targeting

    Article • Journal of Biological Chemistry, November 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  163. The Chaperone BiP/GRP78 Binds to Amyloid Precursor Protein and Decreases Aβ40 and Aβ42 Secretion

    Article • Journal of Biological Chemistry, October 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  164. X11 Interaction with β-Amyloid Precursor Protein Modulates Its Cellular Stabilization and Reduces Amyloid β-Protein Secretion

    Article • Journal of Biological Chemistry, August 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  165. The X11α Protein Slows Cellular Amyloid Precursor Protein Processing and Reduces Aβ40 and Aβ42 Secretion

    Article • Journal of Biological Chemistry, June 1998, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr. Raymond Scott Turner

  166. Probable diffuse Lewy body disease presenting as REM sleep behavior disorder

    Article • Neurology, August 1997, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  167. Vaccinia virus serves as an efficient vector for expressing heterologous proteins in human NTera 2 neurons

    Article • The Journal of Comparative Neurology, October 1996, Wiley

    Dr. Raymond Scott Turner

  168. Amyloids and Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation

    Article • Journal of Biological Chemistry, April 1996, Elsevier

    Dr. Raymond Scott Turner

  169. Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia

    Article • Annals of Neurology, February 1996, Wiley

    Dr. Raymond Scott Turner

  170. Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides.

    Article • Proceedings of the National Academy of Sciences, October 1993, Proceedings of the National Academy of Sciences

    Dr. Raymond Scott Turner

  171. Phospholipid/calcium-dependent protein kinase (protein kinase C) system: A major site of bioregulation

    Article • Advances in Enzyme Regulation, January 1986, Elsevier

    Dr. Raymond Scott Turner

  172. Synthetic myelin basic protein peptide analogs are specific inhibitors of phospholipid/calcium-dependent protein kinase (protein kinase C)

    Article • Biochemical and Biophysical Research Communications, January 1986, Elsevier

    Dr. Raymond Scott Turner

  173. Correlation of the MMPI with Lumbosacral Spine Fusion Results

    Article • Spine, December 1985, Wolters Kluwer Health

    Dr. Raymond Scott Turner

  174. Phospholipid-Sensitive Ca2+-Dependent Protein Kinase Preferentially Phosphorylates Serine-115 of Bovine Myelin Basic Protein

    Article • Journal of Neurochemistry, November 1984, Wiley

    Dr. Raymond Scott Turner

  175. Developmental studies of phospholipid-sensitive Ca2+-dependent protein kinase and its substrates and of phosphoprotein phosphatases in rat brain.

    Article • Proceedings of the National Academy of Sciences, May 1984, Proceedings of the National Academy of Sciences

    Dr. Raymond Scott Turner

  176. Phospholipid-sensitive Ca2+-dependent protein kinase: a major protein phosphorylation system

    Article • Molecular and Cellular Endocrinology, May 1984, Elsevier

    Dr. Raymond Scott Turner

  177. S-100 and Other Acidic Proteins Promote Ca2+-Independent Phosphorylation of Protamine Catalyzed by a New Protein Kinase from Brain

    Article • Journal of Neurochemistry, February 1984, Wiley

    Dr. Raymond Scott Turner

  178. Phospholipid-sensitive Ca2+-dependent protein kinase inhibition by R-24571, A calmodulin antagonist

    Article • Biochemical Pharmacology, January 1984, Elsevier

    Dr. Raymond Scott Turner

  179. Polyamines inhibit phospholipid-sensitive and calmodulin-sensitive Ca2+-dependent protein kinases

    Article • Biochemical Journal, August 1983, Portland Press Ltd.

    Dr. Raymond Scott Turner

  180. Comparative abilities of lanthanide ions La3+ and Tb3+ to substitute for Ca2+ in regulating phospholipid-sensitive Ca2+-dependent protein kinase and myosin light chain kinase

    Article • Life Sciences, July 1983, Elsevier

    Dr. Raymond Scott Turner

  181. Cobra polypeptide cytotoxin I and marine worm polypeptide cytotoxin A-IV are potent and selective inhibitors of phospholipid-sensitive Ca2+ -dependent protein kinase

    Article • FEBS Letters, March 1983, Wiley

    Dr. Raymond Scott Turner

  182. Basic Protein in Brain Myelin Is Phosphorylated by Endogenous Phospholipid-Sensitive Ca2+-Dependent Protein Kinase

    Article • Journal of Neurochemistry, November 1982, Wiley

    Dr. Raymond Scott Turner

  183. Inhibition by melittin of phospholipid-sensitive and calmodulin-sensitive Ca2+ -dependent protein kinases

    Article • Biochemical Journal, January 1982, Portland Press Ltd.

    Dr. Raymond Scott Turner

  184. Methionine-enkephalin and morphine: Amount ejected microiontophoretically

    Article • Journal of Neuroscience Methods, August 1981, Elsevier

    Dr. Raymond Scott Turner

  185. FUNCTIONAL ANATOMY OF BRACHIUM PONTIS

    Article • Journal of Neurophysiology, March 1941, American Physiological Society

    Dr. Raymond Scott Turner